ENCell Co., Ltd. (KOSDAQ:456070)

Market Cap	131.37B
Revenue (ttm)	5.83B
Net Income (ttm)	-18.24B
Shares Out	10.90M
EPS (ttm)	-1,763.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	124,937
Average Volume	122,634
Open	12,130
Previous Close	12,050
Day's Range	12,130 - 12,800
52-Week Range	10,000 - 22,800
Beta	n/a
RSI	46.35
Earnings Date	n/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 456070

Financial Performance

In 2024, ENCell's revenue was 7.21 billion, a decrease of -31.51% compared to the previous year's 10.53 billion. Losses were -15.21 billion, 201.0% more than in 2023.